BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/10/2023 9:15:29 AM | Browse: 471 | Download: 1138
 |
Received |
|
2022-10-12 21:31 |
 |
Peer-Review Started |
|
2022-10-12 21:35 |
 |
First Decision by Editorial Office Director |
|
2022-11-15 03:31 |
 |
Return for Revision |
|
2022-11-15 03:31 |
 |
Revised |
|
2022-11-22 14:44 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2023-01-09 04:02 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2023-01-09 22:34 |
 |
Articles in Press |
|
2023-01-09 22:34 |
 |
Edit the Manuscript by Language Editor |
|
2023-01-15 21:53 |
 |
Typeset the Manuscript |
|
2023-01-30 07:07 |
 |
Publish the Manuscript Online |
|
2023-02-10 09:15 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Virology |
| Manuscript Type |
Review |
| Article Title |
Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Michał Brzdęk, Dorota Zarębska-Michaluk, Federica Invernizzi, Marta Cilla, Krystyna Dobrowolska and Robert Flisiak |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dorota Zarębska-Michaluk, PhD, Professor, Department of Infectious Diseases, Jan Kochanowski University, Radiowa 7, Kielce 25-516, Poland. dorota1010@tlen.pl |
| Key Words |
Hepatitis C virus; Interferon; Direct-acting antiviral; Epidemiology; Chronic hepatitis C |
| Core Tip |
The decade ago, direct-acting antiviral drugs were introduced that have greatly improved the effectiveness of treatment for patients with hepatitis C virus (HCV) infection. The new drugs have increased the chances of eliminating HCV infection as a significant public threat. This paper describes changes in the therapeutic options administered over the past decade and documents the changing patient profile over the years in the interferon (IFN)-free era. Special populations of difficult-to-treat patients in the IFN era, currently not meeting this definition, are highlighted. |
| Publish Date |
2023-02-10 09:15 |
| Citation |
Brzdęk M, Zarębska-Michaluk D, Invernizzi F, Cilla M, Dobrowolska K, Flisiak R. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. World J Gastroenterol 2023; 29(6): 949-966 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i6/949.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i6.949 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.